{
    "root": "1501a154-5d23-4ff0-a6ef-31715dcb2282",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sirolimus",
    "value": "20250527",
    "ingredients": [
        {
            "name": "SIROLIMUS",
            "code": "W36ZG6FT64",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9168"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "SOYBEAN PHOSPHATIDYLCHOLINE",
            "code": "1T6N4D9YV6",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64482"
        },
        {
            "name": "ASCORBYL PALMITATE",
            "code": "QN83US2B0N",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_140768"
        },
        {
            "name": "GLYCERYL MONO- AND DIPALMITOSTEARATE",
            "code": "KC98RO82HJ",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11250"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "SOY ACID",
            "code": "HBA528N3PW",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "sirolimus mtor inhibitor immunosuppressant indicated prophylaxis organ rejection patients aged \u226513 years receiving renal transplants : \u2022 patients low- moderate-immunologic risk : initially cyclosporine ( csa ) corticosteroids . csa withdrawal recommended 2\u20134 months transplantation ( 1.1 ) . \u2022 patients high-immunologic risk : combination csa corticosteroids first 12 months following transplantation ( 1.1 ) . safety efficacy csa withdrawal established high risk patients ( 1.1 , 1.2 , 14.3 ) . sirolimus mtor inhibitor indicated treatment patients lymphangioleiomyomatosis ( 1.3 ) .",
        "doid_entities": [
            {
                "text": "lymphangioleiomyomatosis (DOID:3319)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3319"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "sirolimus administered orally daily , consistently without food [ ( 2.5 ) , pharmacology ( 12.3 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "since sirolimus absorbed skin , special . however , direct contact oral solution occurs skin eyes , wash skin thoroughly soap water ; rinse eyes plain water . sirolimus expiration date . expiration date refers last day month .",
    "adverseReactions": "sirolimus contraindicated patients hypersensitivity sirolimus [ ( 5.4 ) ] .",
    "indications_original": "Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged \u226513 years receiving renal transplants: \u2022 Patients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2\u20134 months after transplantation ( 1.1 ). \u2022 Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). Sirolimus is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ).",
    "contraindications_original": "Sirolimus is to be administered orally once daily, consistently with or without food [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)\n                     ].",
    "warningsAndPrecautions_original": "Since sirolimus is not absorbed through the skin, there are no special precautions. However, if direct contact of the oral solution occurs with the skin or eyes, wash skin thoroughly with soap and water; rinse eyes with plain water.\n                  Do not use sirolimus after the expiration date. The expiration date refers to the last day of that month.",
    "adverseReactions_original": "Sirolimus is contraindicated in patients with a hypersensitivity to sirolimus [see Warnings and Precautions (5.4)\n                     ].",
    "drug": [
        {
            "name": "Sirolimus",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9168"
        }
    ]
}